ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1NVDA | NVIDIA CORP | Technology | $4.01T | 29.27% |
2LLY | ELI LILLY & CO | Healthcare | $1.34T | 9.81% |
3JNJ | JOHNSON & JOHNSON | Healthcare | $682.52B | 4.99% |
4ABBV | ABBVIE INC | Healthcare | $520.47B | 3.80% |
5KO | COCA COLA CO | Consumer Defensive | $419.18B | 3.06% |
6MRK | MERCK & CO INC | Healthcare | $362.27B | 2.65% |
7AMGN | AMGEN INC | Healthcare | $252.64B | 1.85% |
8GEV | GE VERNOVA INC | Utilities | $216.64B | 1.58% |
9GILD | GILEAD SCIENCES INC | Healthcare | $208.31B | 1.52% |
10PEP | PEPSICO INC | Consumer Defensive | $193.86B | 1.42% |
11ABT | ABBOTT LABORATORIES | Healthcare | $185.75B | 1.36% |
12NEE | NEXTERA ENERGY INC | Utilities | $178.88B | 1.31% |
13PFE | PFIZER INC | Healthcare | $164.33B | 1.20% |
14ISRG | INTUITIVE SURGICAL INC | Healthcare | $152.49B | 1.11% |
15VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $137.57B | 1.01% |
16SNDK | SANDISK CORP | Technology | $133.39B | 0.97% |
17APP | APPLOVIN CORP | Technology | $130.43B | 0.95% |
18MDT | MEDTRONIC PLC | Healthcare | $129.18B | 0.94% |
19BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $127.39B | 0.93% |
20SYK | STRYKER CORP | Healthcare | $118.92B | 0.87% |
21NEM | NEWMONT CORP | Basic Materials | $117.05B | 0.86% |
22WDC | WESTERN DIGITAL CORP | Technology | $116.49B | 0.85% |
23SO | SOUTHERN CO | Utilities | $107.66B | 0.79% |
24DUK | DUKE ENERGY CORP | Utilities | $100.26B | 0.73% |
25CEG | CONSTELLATION ENERGY CORP | Utilities | $99.29B | 0.73% |
26REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $98.40B | 0.72% |
27MMM | 3M CO | Industrials | $96.24B | 0.70% |
28WMB | WILLIAMS COMPANIES INC | Energy | $86.81B | 0.63% |
29MDLZ | MONDELEZ INTERNATIONAL INC | Consumer Defensive | $84.25B | 0.62% |
30EPD | ENTERPRISE PRODUCTS PARTNERS LP | Energy | $80.66B | 0.59% |
31KMI | KINDER MORGAN INC | Energy | $71.31B | 0.52% |
32AEP | AMERICAN ELECTRIC POWER CO INC | Utilities | $70.19B | 0.51% |
33BSX | BOSTON SCIENTIFIC CORP | Healthcare | $64.07B | 0.47% |
34TRGP | TARGA RESOURCES CORP | Energy | $63.57B | 0.46% |
35LNG | CHENIERE ENERGY INC | Energy | $63.20B | 0.46% |
36EW | EDWARDS LIFESCIENCES CORP | Healthcare | $60.84B | 0.44% |
37D | DOMINION ENERGY INC | Utilities | $59.38B | 0.43% |
38BDX | BECTON DICKINSON & CO | Healthcare | $58.76B | 0.43% |
39OKE | ONEOK INC | Energy | $56.02B | 0.41% |
40IDXX | IDEXX LABORATORIES INC | Healthcare | $54.99B | 0.40% |
41ETR | ENTERGY CORP | Utilities | $53.49B | 0.39% |
42MDLN | MEDLINE INC | Healthcare | $52.59B | 0.38% |
43XEL | XCEL ENERGY INC | Utilities | $52.31B | 0.38% |
44SRE | SEMPRA | Utilities | $51.66B | 0.38% |
45TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $50.93B | 0.37% |
46KDP | KEURIG DR PEPPER INC | Consumer Defensive | $48.20B | 0.35% |
47ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 0.35% |
48EXC | EXELON CORP | Utilities | $47.22B | 0.35% |
49VST | VISTRA CORP | Utilities | $45.65B | 0.33% |
50ED | CONSOLIDATED EDISON INC | Utilities | $44.29B | 0.32% |
51RPRX | ROYALTY PHARMA PLC | Healthcare | $39.56B | 0.29% |
52WEC | WEC ENERGY GROUP INC | Utilities | $38.65B | 0.28% |
53PEG | PUBLIC SERVICE ENTERPRISE GROUP INC | Utilities | $37.29B | 0.27% |
54BIIB | BIOGEN INC | Healthcare | $37.03B | 0.27% |
55GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $37.00B | 0.27% |
56HSY | HERSHEY CO | Consumer Defensive | $34.83B | 0.25% |
57PCG | PG&E CORP | Utilities | $34.76B | 0.25% |
58ADM | ARCHER-DANIELS-MIDLAND CO | Consumer Defensive | $33.78B | 0.25% |
59ZTS | ZOETIS INC | Healthcare | $33.71B | 0.25% |
60RMD | RESMED INC | Healthcare | $33.60B | 0.25% |
61VG | VENTURE GLOBAL INC | Energy | $33.38B | 0.24% |
62AEE | AMEREN CORP | Utilities | $31.44B | 0.23% |
63DXCM | DEXCOM INC | Healthcare | $30.35B | 0.22% |
64ATO | ATMOS ENERGY CORP | Utilities | $29.73B | 0.22% |
65CQP | CHENIERE ENERGY PARTNERS LP | Energy | $29.72B | 0.22% |
66AWK | AMERICAN WATER WORKS COMPANY INC | Utilities | $29.38B | 0.21% |
67OTIS | OTIS WORLDWIDE CORP | Industrials | $29.37B | 0.21% |
68KHC | KRAFT HEINZ CO | Consumer Defensive | $28.98B | 0.21% |
69DTE | DTE ENERGY CO | Utilities | $28.98B | 0.21% |
70ROIV | ROIVANT SCIENCES LTD | Healthcare | $28.98B | 0.21% |
71VRSN | VERISIGN INC | Technology | $28.03B | 0.20% |
72CNP | CENTERPOINT ENERGY INC | Utilities | $27.14B | 0.20% |
73FE | FIRSTENERGY CORP | Utilities | $26.92B | 0.20% |
74ES | EVERSOURCE ENERGY | Utilities | $26.83B | 0.20% |
75PPL | PPL CORP | Utilities | $26.50B | 0.19% |
76UTHR | UNITED THERAPEUTICS CORP | Healthcare | $25.27B | 0.18% |
77STE | STERIS PLC | Healthcare | $24.61B | 0.18% |
78STZ | CONSTELLATION BRANDS INC | Consumer Defensive | $24.47B | 0.18% |
79VTRS | VIATRIS INC | Healthcare | $23.70B | 0.17% |
80EIX | EDISON INTERNATIONAL | Utilities | $23.08B | 0.17% |
81NI | NISOURCE INC | Utilities | $21.97B | 0.16% |
82CMS | CMS ENERGY CORP | Utilities | $21.71B | 0.16% |
83ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $20.98B | 0.15% |
84TSN | TYSON FOODS INC | Consumer Defensive | $20.85B | 0.15% |
85EVRG | EVERGY INC | Utilities | $20.70B | 0.15% |
86NRG | NRG ENERGY INC | Utilities | $20.59B | 0.15% |
87ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $19.79B | 0.14% |
88BG | BUNGE GLOBAL SA | Consumer Defensive | $19.21B | 0.14% |
89LNT | ALLIANT ENERGY CORP | Utilities | $18.95B | 0.14% |
90GIS | GENERAL MILLS INC | Consumer Defensive | $17.92B | 0.13% |
91WES | WESTERN MIDSTREAM PARTNERS LP | Energy | $17.26B | 0.13% |
92NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.15B | 0.13% |
93TLN | TALEN ENERGY CORP | Utilities | $16.82B | 0.12% |
94JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.43B | 0.11% |
95SOLV | SOLVENTUM CORP | Healthcare | $15.07B | 0.11% |
96SJM | J M SMUCKER CO | Consumer Defensive | $14.07B | 0.10% |
97BF.B | BROWN FORMAN CORP | Consumer Defensive | $13.78B | 0.10% |
98BAX | BAXTER INTERNATIONAL INC | Healthcare | $13.32B | 0.10% |
99ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $13.25B | 0.10% |
100PNW | PINNACLE WEST CAPITAL CORP | Utilities | $12.97B | 0.09% |
101WTRG | ESSENTIAL UTILITIES INC | Utilities | $12.79B | 0.09% |
102PEN | PENUMBRA INC | Healthcare | $12.64B | 0.09% |
103MKC | MCCORMICK & CO INC | Consumer Defensive | $12.49B | 0.09% |
104DTM | DT MIDSTREAM INC | Energy | $12.20B | 0.09% |
105HRL | HORMEL FOODS CORP | Consumer Defensive | $12.01B | 0.09% |
106COO | COOPER COMPANIES INC | Healthcare | $11.83B | 0.09% |
107ALGN | ALIGN TECHNOLOGY INC | Healthcare | $11.77B | 0.09% |
108HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 0.08% |
109TECH | BIO-TECHNE CORP | Healthcare | $11.44B | 0.08% |
110BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $10.98B | 0.08% |
111RGEN | REPLIGEN CORP | Healthcare | $10.64B | 0.08% |
112OGE | OGE ENERGY CORP | Utilities | $10.60B | 0.08% |
113PODD | INSULET CORP | Healthcare | $10.36B | 0.08% |
114TGTX | TG THERAPEUTICS INC | Healthcare | $9.76B | 0.07% |
115AM | ANTERO MIDSTREAM CORP | Energy | $9.64B | 0.07% |
116GMED | GLOBUS MEDICAL INC | Healthcare | $9.58B | 0.07% |
117KRYS | KRYSTAL BIOTECH INC | Healthcare | $9.06B | 0.07% |
118KNTK | KINETIK HOLDINGS INC | Energy | $8.85B | 0.06% |
119PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $8.77B | 0.06% |
120IDA | IDACORP INC | Utilities | $8.61B | 0.06% |
121DAR | DARLING INGREDIENTS INC | Consumer Defensive | $8.58B | 0.06% |
122CORT | CORCEPT THERAPEUTICS INC | Healthcare | $8.07B | 0.06% |
123UGI | UGI CORP | Utilities | $8.04B | 0.06% |
124ALKS | ALKERMES PLC | Healthcare | $7.89B | 0.06% |
125LW | LAMB WESTON HOLDINGS INC | Consumer Defensive | $7.61B | 0.06% |
126KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $7.56B | 0.06% |
127AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $7.56B | 0.06% |
128BLCO | BAUSCH & LOMB CORP | Healthcare | $7.56B | 0.06% |
129SFD | SMITHFIELD FOODS INC | Consumer Defensive | $7.47B | 0.05% |
130NFG | NATIONAL FUEL GAS CO | Energy | $7.26B | 0.05% |
131ORKA | ORUKA THERAPEUTICS INC | Healthcare | $7.12B | 0.05% |
132CAG | CONAGRA BRANDS INC | Consumer Defensive | $6.95B | 0.05% |
133TAP | MOLSON COORS BEVERAGE CO | Consumer Defensive | $6.95B | 0.05% |
134CWEN | CLEARWAY ENERGY INC | Utilities | $6.85B | 0.05% |
135SWX | SOUTHWEST GAS HOLDINGS INC | Utilities | $6.75B | 0.05% |
136MSA | MSA SAFETY INC | Industrials | $6.73B | 0.05% |
137BKH | BLACK HILLS CORP | Utilities | $6.70B | 0.05% |
138LNTH | LANTHEUS HOLDINGS INC | Healthcare | $6.62B | 0.05% |
139CPB | CAMPBELL'S CO | Consumer Defensive | $6.58B | 0.05% |
140PPC | PILGRIMS PRIDE CORP | Consumer Defensive | $6.49B | 0.05% |
141TXNM | TXNM ENERGY INC | Utilities | $6.48B | 0.05% |
142LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.33B | 0.05% |
143TFX | TELEFLEX INC | Healthcare | $6.07B | 0.04% |
144INGR | INGREDION INC | Consumer Defensive | $5.78B | 0.04% |
145HAE | HAEMONETICS CORP | Healthcare | $5.59B | 0.04% |
146NJR | NEW JERSEY RESOURCES CORP | Utilities | $5.58B | 0.04% |
147ORA | ORMAT TECHNOLOGIES INC | Utilities | $5.56B | 0.04% |
148POR | PORTLAND GENERAL ELECTRIC CO | Utilities | $5.43B | 0.04% |
149PTCT | PTC THERAPEUTICS INC | Healthcare | $5.29B | 0.04% |
150NWE | NORTHWESTERN ENERGY GROUP INC | Utilities | $5.27B | 0.04% |
151SR | SPIRE INC | Utilities | $5.21B | 0.04% |
152MMSI | MERIT MEDICAL SYSTEMS INC | Healthcare | $5.19B | 0.04% |
153OGS | ONE GAS INC | Utilities | $5.19B | 0.04% |
154POWL | POWELL INDUSTRIES INC | Industrials | $5.17B | 0.04% |
155EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $5.02B | 0.04% |
156LIVN | LIVANOVA PLC | Healthcare | $4.97B | 0.04% |
157OKLO | OKLO INC | Utilities | $4.77B | 0.03% |
158AROC | ARCHROCK INC | Energy | $4.75B | 0.03% |
159KGS | KODIAK GAS SERVICES INC | Energy | $4.50B | 0.03% |
160ICUI | ICU MEDICAL INC | Healthcare | $4.43B | 0.03% |
161EE | EXCELERATE ENERGY INC | Energy | $4.30B | 0.03% |
162NVST | ENVISTA HOLDINGS CORP | Healthcare | $3.95B | 0.03% |
163COCO | VITA COCO COMPANY INC | Consumer Defensive | $3.69B | 0.03% |
164OGN | ORGANON & CO | Healthcare | $3.65B | 0.03% |
165AWR | AMERICAN STATES WATER CO | Utilities | $3.52B | 0.03% |
166POST | POST HOLDINGS INC | Consumer Defensive | $3.50B | 0.03% |
167ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.48B | 0.03% |
168CPK | CHESAPEAKE UTILITIES CORP | Utilities | $3.43B | 0.03% |
169AVA | AVISTA CORP | Utilities | $3.37B | 0.02% |
170WRBY | WARBY PARKER INC | Healthcare | $3.32B | 0.02% |
171AXGN | AXOGEN INC | Healthcare | $3.31B | 0.02% |
172TMDX | TRANSMEDICS GROUP INC | Healthcare | $3.20B | 0.02% |
173OTTR | OTTER TAIL CORP | Utilities | $3.16B | 0.02% |
174IRTC | IRHYTHM HOLDINGS INC | Healthcare | $3.15B | 0.02% |
175ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $3.14B | 0.02% |
176FRPT | FRESHPET INC | Consumer Defensive | $3.12B | 0.02% |
177CWT | CALIFORNIA WATER SERVICE GROUP | Utilities | $3.11B | 0.02% |
178BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 0.02% |
179XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $3.04B | 0.02% |
180MZTI | MARZETTI CO | Consumer Defensive | $3.01B | 0.02% |
181MGEE | MGE ENERGY INC | Utilities | $2.99B | 0.02% |
182HTO | H2O AMERICA | Utilities | $2.94B | 0.02% |
183ADMA | ADMA BIOLOGICS INC | Healthcare | $2.94B | 0.02% |
184VCEL | VERICEL CORP | Healthcare | $2.93B | 0.02% |
185ATRC | ATRICURE INC | Healthcare | $2.85B | 0.02% |
186TR | TOOTSIE ROLL INDUSTRIES INC | Consumer Defensive | $2.84B | 0.02% |
187NEOG | NEOGEN CORP | Healthcare | $2.44B | 0.02% |
188UFPT | UFP TECHNOLOGIES INC | Healthcare | $2.37B | 0.02% |
189CTRI | CENTURI HOLDINGS INC | Utilities | $2.25B | 0.02% |
190SAM | BOSTON BEER CO INC | Consumer Defensive | $2.23B | 0.02% |
191NWN | NORTHWEST NATURAL HOLDING CO | Utilities | $2.18B | 0.02% |
192AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.17B | 0.02% |
193PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.15B | 0.02% |
194SUPN1 | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.11B | 0.02% |
195UTZ | UTZ BRANDS INC | Consumer Defensive | $2.05B | 0.01% |
196HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.98B | 0.01% |
197NGL | NGL ENERGY PARTNERS LP | Energy | $1.95B | 0.01% |
198XRAY | DENTSPLY SIRONA INC | Healthcare | $1.83B | 0.01% |
199ZYME | ZYMEWORKS INC | Healthcare | $1.83B | 0.01% |
200LMAT | LEMAITRE VASCULAR INC | Healthcare | $1.78B | 0.01% |
201ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.77B | 0.01% |
202INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.75B | 0.01% |
203NEXT | NEXTDECADE CORP | Energy | $1.75B | 0.01% |
204SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.01% |
205NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.01% |
206JJSF | J&J SNACK FOODS CORP | Consumer Defensive | $1.64B | 0.01% |
207ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.62B | 0.01% |
208IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.57B | 0.01% |
209CNMD | CONMED CORP | Healthcare | $1.50B | 0.01% |
210HE | HAWAIIAN ELECTRIC INDUSTRIES INC | Utilities | $1.49B | 0.01% |
211EYE | NATIONAL VISION HOLDINGS INC | Consumer Cyclical | $1.47B | 0.01% |
212PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.46B | 0.01% |
213PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.01% |
214ANAB | ANAPTYSBIO INC | Healthcare | $1.43B | 0.01% |
215CDRE | CADRE HOLDINGS INC | Industrials | $1.42B | 0.01% |
216PBT | PERMIAN BASIN ROYALTY TRUST | Energy | $1.41B | 0.01% |
217INVA | INNOVIVA INC | Healthcare | $1.35B | 0.01% |
218STAA | STAAR SURGICAL CO | Healthcare | $1.34B | 0.01% |
219OMER | OMEROS CORP | Healthcare | $1.30B | 0.01% |
220FLO | FLOWERS FOODS INC | Consumer Defensive | $1.27B | 0.01% |
221AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $1.23B | 0.01% |
222TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.22B | 0.01% |
223AMSC | AMERICAN SUPERCONDUCTOR CORP | Industrials | $1.21B | 0.01% |
224BRBR | BELLRING BRANDS INC | Consumer Defensive | $1.19B | 0.01% |
225VOR | VOR BIOPHARMA INC | Healthcare | $1.19B | 0.01% |
226SENEA | SENECA FOODS CORP | Consumer Defensive | $1.14B | 0.01% |
227IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.12B | 0.01% |
228SMPL | SIMPLY GOOD FOODS CO | Consumer Defensive | $1.10B | 0.01% |
229MSEX | MIDDLESEX WATER CO | Utilities | $1.10B | 0.01% |
230IRMD | IRADIMED CORP | Healthcare | $1.09B | 0.01% |
231SIBN | SI-BONE INC | Healthcare | $1.09B | 0.01% |
232HROW | HARROW INC | Healthcare | $1.06B | 0.01% |
233UTL | UNITIL CORP | Utilities | $1.03B | 0.01% |
234CYRX | CRYOPORT INC | Industrials | $1.02B | 0.01% |
235WINA | WINMARK CORP | Consumer Cyclical | $967M | 0.01% |
236AORT | ARTIVION INC | Healthcare | $947M | 0.01% |
237BVS | BIOVENTUS INC | Healthcare | $915M | 0.01% |
238RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $860M | 0.01% |
239KIDS | ORTHOPEDIATRICS CORP | Healthcare | $851M | 0.01% |
240MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $844M | 0.01% |
241WEST | WESTROCK COFFEE CO | Consumer Defensive | $841M | 0.01% |
242COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $775M | 0.01% |
243DCTH | DELCATH SYSTEMS INC | Healthcare | $744M | 0.01% |
244QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.01% |
245XIFR | XPLR INFRASTRUCTURE LP | Utilities | $692M | 0.01% |
246ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $664M | 0.00% |
247JBSS | SANFILIPPO JOHN B & SON INC | Consumer Defensive | $657M | 0.00% |
248MAMA | MAMA'S CREATIONS INC | Consumer Defensive | $624M | 0.00% |
249TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $601M | 0.00% |
250NNE | NANO NUCLEAR ENERGY INC | Industrials | $596M | 0.00% |
251YORW | YORK WATER CO | Utilities | $512M | 0.00% |
252GNE | GENIE ENERGY LTD | Utilities | $494M | 0.00% |
253ARVN | ARVINAS INC | Healthcare | $450M | 0.00% |
254SMC | SUMMIT MIDSTREAM CORP | Energy | $428M | 0.00% |
255OFRM | ONCE UPON A FARM PBC | Consumer Defensive | $428M | 0.00% |
256PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.00% |
257ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $411M | 0.00% |
258CWCO | CONSOLIDATED WATER CO LTD | Utilities | $405M | 0.00% |
259VITL | VITAL FARMS INC | Consumer Defensive | $385M | 0.00% |
260FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $382M | 0.00% |
261EMBC | EMBECTA CORP | Healthcare | $364M | 0.00% |
262ARTNA | ARTESIAN RESOURCES CORP | Utilities | $336M | 0.00% |
263LWAY | LIFEWAY FOODS INC | Consumer Defensive | $316M | 0.00% |
264AGEN | AGENUS INC | Healthcare | $311M | 0.00% |
265IDR | IDAHO STRATEGIC RESOURCES INC | Basic Materials | $300M | 0.00% |
266INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $296M | 0.00% |
267UCFI | CN HEALTHY FOOD TECH GROUP CORP | Consumer Defensive | $288M | 0.00% |
268OFIX | ORTHOFIX MEDICAL INC | Healthcare | $283M | 0.00% |
269QTTB | Q32 BIO INC | Healthcare | $264M | 0.00% |
270PCYO | PURE CYCLE CORP | Utilities | $261M | 0.00% |
271BRCC | BRC INC | Consumer Defensive | $241M | 0.00% |
272USNA | USANA HEALTH SCIENCES INC | Consumer Defensive | $235M | 0.00% |
273UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $234M | 0.00% |
274RGCO | RGC RESOURCES INC | Utilities | $234M | 0.00% |
275PDEX | PRO DEX INC | Healthcare | $216M | 0.00% |
276ELMD | ELECTROMED INC | Healthcare | $204M | 0.00% |
277GWRS | GLOBAL WATER RESOURCES INC | Utilities | $202M | 0.00% |
278ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.00% |
279NATR | NATURES SUNSHINE PRODUCTS INC | Consumer Defensive | $178M | 0.00% |
280MED | MEDIFAST INC | Consumer Cyclical | $144M | 0.00% |
281SKIN | SKINHEALTH SYSTEMS INC | Consumer Defensive | $104M | 0.00% |
282BYND | BEYOND MEAT INC | Consumer Defensive | $102M | 0.00% |
283ICCC | IMMUCELL CORP | Healthcare | $93M | 0.00% |
284SIMA | SIM ACQUISITION CORP I | Financial Services | $90M | 0.00% |
285RLYB | RALLYBIO CORP | Healthcare | $84M | 0.00% |
286FTLF | FITLIFE BRANDS INC | Consumer Defensive | $78M | 0.00% |
287APT | ALPHA PRO TECH LTD | Industrials | $64M | 0.00% |
288LFVN | LIFEVANTAGE CORP | Consumer Defensive | $64M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $13.68T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Days required to liquidate the largest position at 20% of one day's dollar volume.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T032403 rates=20261113T032429
Measured on the 2026-11 formation date across 288 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Publication date unknown. We don’t have a source year for this signal, so we can’t split its record into before and since publication. That’s a gap in our reference data — not a statement about how the factor performed.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 7.6% | 21.6% |
| 3 yearsp.a. | 23.3% | 10.8% |
| 5 yearsp.a. | 9.7% | 9.2% |
| 10 yearsp.a. | 11.0% | 5.9% |
| Since inceptionp.a. | 8.6% | 4.2% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 5.8% | 18.5% |
| 2025 | 31.1% | 18.2% |
| 2024 | 28.2% | 1.9% |
| 2023 | 17.3% | -3.8% |
| 2022 | -26.8% | 5.3% |
| 2021 | 20.3% | 8.3% |
| 2020 | 14.8% | -4.8% |
| 2019 | 18.7% | 6.5% |
| 2018 | 1.5% | 22.3% |
| 2017 | 10.0% | -7.1% |
| 2016 | 4.3% | -14.1% |
| 2015 | 5.1% | 29.4% |
| 2014 | 22.9% | 33.7% |
| 2013 | 30.8% | 1.5% |
| 2012 | 13.8% | 5.0% |
| 2011 | 8.6% | 4.8% |
| 2010 | 7.3% | -14.8% |
| 2009 | 34.1% | -14.9% |
| 2008 | -29.0% | 48.8% |
| 2007 | 9.4% | 13.5% |
| 2006 | 10.9% | -12.0% |
| 2005 | 14.1% | 3.5% |
| 2004 | 10.0% | -5.2% |
| 2003 | 24.1% | -11.7% |
| 2002 | -23.3% | -2.2% |
| 2001 | -12.6% | 11.7% |
| 2000 | -8.5% | -2.1% |
| 1999 | 40.3% | 6.0% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Return on Assets Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a Return on Assets signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,140-name universe at November 2026. Rows: Large ≥ $5.3B, Small < $832M. Columns: Value ≥ 0.62, Growth < 0.33 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 82% toward Growth. +3% unclassified (23 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 288 names now. Hypothetical holdings — descriptive, not P&L.